Pharmaceutical - Markets & Marketing, Abbott Laboratories


Popular Filters

India’s patents moves could see particular uncertainty for diabetes sector

India’s patents moves could see particular uncertainty for diabetes sector


The Indian government's decision to review patented drugs by multinationals, to allow for the manufacture…

Abbott LaboratoriesAsia-PacificDiabetesEli LillyIndiaMarkets & MarketingMerck & CoNovo NordiskPatentsPharmaceutical

Patient trust in drugmakers declining, new report shows


Increasing numbers of pharmaceutical companies are seeking to redefine their relationships with patients,…

Abbott LaboratoriesBiotechnologyEli LillyGilead SciencesGlaxoSmithKlineGlobalJanssenLundbeckMarkets & MarketingNovartisNovo NordiskPfizerPharmaceuticalPricingResearchRoche

Global rheumatology market controlled by Enbrel, Humira and Remicade


The global rheumatology therapeutics market has been forecast to increase at a compound annual growth…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyCelebrexEnbrelGlaxoSmithKlineGlobalHumiraMarkets & MarketingPfizerPharmaceuticalRemicadeTakeda PharmaceuticalsUloric

Abbott launches Sucampo's Amitiza in Japan


US drugmaker Sucampo Pharmaceuticals (Nasdaq: SCMP), and marketing partner health care major Abbott Laboratories…

Abbott LaboratoriesAmitizaAsia-PacificGastro-intestinalsMarkets & MarketingPharmaceuticalSucampo

Bristol-Myers' subcutaneous Orencia OKed in EU; Biologics for RA


US drug major Bristol-Myers Squibb (NYSE: BMY) announced on Friday that the European Commission has granted…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEnbrelEuropeHumiraMarkets & MarketingNorth AmericaOrenciaPfizerPharmaceuticalRegulation

Abbott Labs sentenced for misbranding drug; fined $500 million


US health care major Abbott Laboratories (NYSE: ABT) was sentenced by US District Court Judge Samuel…

Abbott LaboratoriesDepakoteFinancialLegalMarkets & MarketingNorth AmericaPharmaceutical

Abbott/Eisai's Humira has emerged as leading psoriasis agent


For the treatment of psoriasis, Abbott/Eisai's Humira (adalimumab) has displaced Amgen/Stiefel/Pfizer/Takeda's…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyEisaiEnbrelGlobalHumiraImmunologicalsJanssenMarkets & MarketingPfizerPharmaceuticalStelara Injection

Abbott Labs agrees $1.6 billion settlement over Depakote marketing practices


Ending a four year investigation, US health care major Abbott Laboratories (NYSE: ABT) has reached a…

Abbott LaboratoriesDepakoteFinancialLegalMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

US gastroenterologists see significant growth for Abbott/Eisai’s Humira in ulcerative colitis once indication is approved


In a recent survey of US gastroenterologists (n=99), BioTrends Research (a Decision Resources company)…

Abbott LaboratoriesBiotechnologyEisaiGastro-intestinalsHumiraMarkets & MarketingNorth AmericaPharmaceuticalRemicade

Back to top